CDC42 and cancer: Increased expression of Cdc42 correlates positively with cancer progression and poor clinical outcome in lung adenocarcinoma32, colorectal cancer33, breast carcinoma34 and melanoma35, which makes Cdc42 an appealing target for cancer therapy.